Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib
CONCLUSIONS: The results of this cost per responder analysis suggest upadacitinib is a cost-effective option for the first- and second-line treatment of moderately to severely active ulcerative colitis in Japan.PMID:38512101 | DOI:10.1080/13696998.2024.2333683 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 21, 2024 Category: Health Management Authors: Masayuki Saruta Isao Kawaguchi Yuji Ogawa Yuri Sanchez Gonzalez Naoki Numajiri Xiaohe Tang Russell Miller Source Type: research
Quantifying preferences for urea cycle disorder treatments using a discrete choice experiment
Conclusions: Among attributes tested, taste/odor was the most important attribute influencing overall preference for both prescribing and patient adherence, with taste/odor masking preferred. Optimizing nitrogen-binding medications through masking taste/odor may support improved patient adherence and outcomes in UCDs.PMID:38491962 | DOI:10.1080/13696998.2024.2330846 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 16, 2024 Category: Health Management Authors: Josiah Edelblut Jeffrey R Skaar John Hilton Matthew Seibt Kyle Martin Nandini Hadker Adrian Quartel Robert D Steiner Source Type: research
Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study
This study assessed the comparative adherence of these ERAs for PAH in Australian patients.Methods: This retrospective, observational study used data for adults with PAH from the Services Australia 10% Pharmaceuticals Benefits Scheme (PBS) dataset (01/2006-10/2020). The primary outcome was treatment adherence (ie, receiving ≥80% of ERA doses over 12 months). Secondary outcomes were time to treatment change (add-on or switch) and overall survival.Results: The study included 436 patients who took bosentan (n = 200), ambrisentan (n = 69), or macitentan (n = 167). Treatment adherence was significantly greater in patients who...
Source: Journal of Medical Economics - March 15, 2024 Category: Health Management Authors: Edmund Lau Eugene Kotlyar Yogeshwar Makanji Dae Young Yu Jin Yu Tan Jeremy Casorso Mahsa H Kouhkamari Sooyeol Lim David Bin-Chia Wu Paul Bloomfield Source Type: research
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma
Conclusion: This simulation demonstrates that treatment with toripalimab generates savings that enable budget-neutral funding for up to an additional 252 regimens with toripalimab-gemcitabine-cisplatin for one full year, the equivalent of approximately 21% of the 2024 incident cases of R/M NPC in the US.PMID:38488887 | DOI:10.1080/13696998.2024.2331905 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 15, 2024 Category: Health Management Authors: Karen MacDonald Marc Pondel Ivo Abraham Source Type: research
Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study
This study assessed the comparative adherence of these ERAs for PAH in Australian patients.Methods: This retrospective, observational study used data for adults with PAH from the Services Australia 10% Pharmaceuticals Benefits Scheme (PBS) dataset (01/2006-10/2020). The primary outcome was treatment adherence (ie, receiving ≥80% of ERA doses over 12 months). Secondary outcomes were time to treatment change (add-on or switch) and overall survival.Results: The study included 436 patients who took bosentan (n = 200), ambrisentan (n = 69), or macitentan (n = 167). Treatment adherence was significantly greater in patients who...
Source: Journal of Medical Economics - March 15, 2024 Category: Health Management Authors: Edmund Lau Eugene Kotlyar Yogeshwar Makanji Dae Young Yu Jin Yu Tan Jeremy Casorso Mahsa H Kouhkamari Sooyeol Lim David Bin-Chia Wu Paul Bloomfield Source Type: research
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma
Conclusion: This simulation demonstrates that treatment with toripalimab generates savings that enable budget-neutral funding for up to an additional 252 regimens with toripalimab-gemcitabine-cisplatin for one full year, the equivalent of approximately 21% of the 2024 incident cases of R/M NPC in the US.PMID:38488887 | DOI:10.1080/13696998.2024.2331905 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 15, 2024 Category: Health Management Authors: Karen MacDonald Marc Pondel Ivo Abraham Source Type: research
